tag patient-perspectives 
Pharmaceutical Technology
APRIL 13, 2023
Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. As per ICER, if a treatment improves quality of life or extends a patient’s life, then this can be represented in additional QALYs provided by the therapy.
Rethinking Clinical Trials
MAY 25, 2023
Aspirin is now the most commonly used VTE prophylaxis for Arthroplasty patients, in which Aspirin and LMWH are both safe and effective prophylaxis options. Aspirin as an oral pill is a less expensive and easier option for the orthopedic trauma population, which has a high proportion of uninsured patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
JUNE 7, 2023
The trial was designed to randomize 1,000 patients who had an On-X aortic valve replacement at least 3 months prior to randomization with either a standard dose of Apixaban (5mg) or continued warfarin (the standard of care). The drugs were administered open label and all patients were given a low dose of aspirin.
Rethinking Clinical Trials
JULY 6, 2023
For instance, there is no discussion of the role of the health care provider in the DCTs, but it emphasizes the importance of patient voice. Discussion Themes -As an early adopter of DCTs, could you share your experience and perspective on these issues? DCTs can make things easier for patients and the research more efficient.
Rethinking Clinical Trials
FEBRUARY 28, 2024
Outcomes including patient reported outcomes, functional assessments including via digital technology, healthcare events or mortality may require identify verification. From my perspective, if one key goal for NIH is to reach people in underserved communities having sound practices for decentralized methods will be important.
XTalks
APRIL 18, 2024
Conversely, a negative result suggests a low probability of amyloid pathology, guiding healthcare providers in clinical decision-making and potentially ruling out Alzheimer’s disease in symptomatic patients. There are currently no FDA-authorized blood tests for detecting Alzheimer’s disease.
XTalks
JUNE 9, 2021
The historic and highly anticipated approval created a flurry of excitement in the Alzheimer’s disease space for patients, healthcare practitioners, advocacy groups and Biogen shareholders alike, as shares of the company jumped more than 50 percent after the announcement. Aducanumab Controversy and Price Tag.
Expert insights. Personalized for you.
147 
Let's personalize your content